Merck Mulls Possible Vioxx Reintroduction

Merck may reconsider its decision to withdraw the COX-2 inhibitor Vioxx in light of a conclusion by some members of an FDA advisory committee that the cardiovascular signal seen with rofecoxib is a class effect